Overview
BPC-157 is classified as a body protective compound peptide. Injury recovery, gut healing, tissue repair, reduced inflammation.
Promotes angiogenesis, collagen deposition, and modulates growth factors for accelerated healing. Acts on multiple repair pathways simultaneously including tendon, ligament, muscle, gut lining, and nerve tissue.
Also known as: Body Protection Compound-157, PL 14736
Category
Body Protective Compound
Half-Life
4h
Route
SubQ
FDA Status
Not Approved
How Does BPC-157 Work?
Promotes angiogenesis, collagen deposition, and modulates growth factors for accelerated healing. Acts on multiple repair pathways simultaneously including tendon, ligament, muscle, gut lining, and nerve tissue.
At the molecular level, BPC-157 operates through pathways characteristic of the Body Protective Compound class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]BPC-157 tendon, ligament, and gut healing effects
Comprehensive review demonstrating potent tendon, ligament, and gut healing effects across multiple preclinical models.
Evidence: preclinical[2]Stable gastric pentadecapeptide BPC 157 gastrointestinal tract healing
Robert et al. demonstrate BPC-157 heals GI ulcers, fistulas, and inflammatory bowel lesions in rats via cytoprotective pathways. Published in Current Pharmaceutical Design.
Evidence: preclinical[3]BPC-157 accelerates Achilles tendon healing in rats
Staresinic et al. show BPC-157 accelerates healing of transected Achilles tendons, enhancing tendon fibroblast outgrowth and survival via FAK-paxillin signaling.
Evidence: preclinical[4]BPC-157 systematic review: musculoskeletal healing (2025)
Systematic review of 35 preclinical and 1 clinical study (1993-2024). BPC-157 promotes angiogenesis, collagen synthesis, and reduces inflammatory cytokines across muscle, tendon, ligament, and bone injury models.
Evidence: preclinical[5]BPC-157 and neuroprotection: stroke and spinal cord models
Preclinical evidence showing BPC-157 counteracts stroke-induced neuronal damage and improves functional recovery after spinal cord compression in rats.
Evidence: preclinical[6]BPC-157 angiogenic and vascular protective effects
Demonstrates BPC-157's strong angiogenic potential via VEGFR2-Akt-eNOS pathway activation, endothelium protection, and reversal of thrombus formation.
Evidence: preclinicalSafety Profile
Excellent research safety profile; commonly used for recovery. Not FDA-approved. Most evidence from animal models. FDA restricted use in compounded medications in Sept 2023.
| Side Effect | Incidence | Severity |
|---|---|---|
| Lightheadedness | ~5% of users | mild |
| Nausea (especially oral route) | ~3-5% of users | mild |
| Vivid dreams | ~5% of users | mild |
| Euphoria / mood lift | ~8% of users | mild |
Sourcing BPC-157 for Research
If you're looking to source BPC-157 for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
Disclosure: PeptiDex may earn a commission from affiliate links. This does not affect our recommendations.
Full Research Profile
BPC-157 — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.